Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innovative Drug List", recently introduced by ...

(Yicai) Dec. 8 -- China introduced its first Commercial Health Insurance Innovative Drug List that includes five chimeric ...

As an electrician, David Clark knows there are countless "niche" risks when he's on the job.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...

Finance Ministry says MHIT coverage can be added as a rider to investment-linked insurance policies, using level premiums and ...

(Yicai) Dec. 9 -- China has included two pricey Alzheimer’s disease treatments from Japan’s Eisai and the US’ Eli Lilly in ...

Following the annual expansion, China's reimbursement list now covers a total of 3,253 drugs — 1,857 Western chemical drugs ...

Starting a small business feels exciting until reality rear-ends you at a stoplight. You’ve got the leash clips, the loyal ...

Nineteen novel drugs have been selected for inclusion in the first iteration of China's Commercial Health Insurance Innovative Drug Catalogue, portending potential access benefits as the program ga | ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently ...